Buy CLDX by Jul 19, 2026.

The firm cited increased conviction for successful Phase 3 results in chronic spontaneous urticaria and positive implications for prurigo nodularis. Barclays had previously held reservations about the value of barzolvolimab in CSU due to safety concerns and risks related to dosing-schedule changes, particularly the introduction of a loading dose in the Phase 3 program. The firm noted that enrollment in the Phase 3 EMBARQ trial completed six months ahead of schedule, with a fourth-quarter readout expected. Barclays said the faster …